Abstract
Cystine knot miniproteins define a class of peptides in the size range of approximately 28-35 amino acid residues that often combine high chemical and biological stability with high potency and selectivity. They share a common structural motif that is defined by three intramolecular disulfide bonds that gives rise to a very stable scaffold. Members of this family cover a broad spectrum of natural bioactivities ranging from antimicrobial and antiviral activities to selective blockage or activation of ion channels, cell surface receptors and extracelluar proteases. In recent years, the spectrum of natural bioactivities of this class of miniproteins was further expanded by application of protein design and directed evolution technologies. Miniproteins have been developed that inhibit platelet aggregation, block asthma-related proteases, act as growth factor mimics or address human tumor targets. Recent reports on miniproteins binding to cancer specific targets indicate that these biomolecules due to their particularly high in vivo stability, high target affinity, good tissue distribution, and fast body clearance are very promising agents that can be endowed with important beneficial features for imaging and therapeutic applications. With the first cystine-knot miniprotein already marketed as an analgesic, more candidates can be expected to find their way into the clinic for diagnostic and therapeutic applications over next years
Keywords: Cystine knot miniprotein, knottin, ICK peptide, conotoxin, tumor imaging, protease inhibition, amino acid residues, scaffold, extracelluar proteases, analgesic
Current Pharmaceutical Design
Title: Natural and Engineered Cystine Knot Miniproteins for Diagnostic and Therapeutic Applications
Volume: 17 Issue: 38
Author(s): Harald Kolmar
Affiliation:
Keywords: Cystine knot miniprotein, knottin, ICK peptide, conotoxin, tumor imaging, protease inhibition, amino acid residues, scaffold, extracelluar proteases, analgesic
Abstract: Cystine knot miniproteins define a class of peptides in the size range of approximately 28-35 amino acid residues that often combine high chemical and biological stability with high potency and selectivity. They share a common structural motif that is defined by three intramolecular disulfide bonds that gives rise to a very stable scaffold. Members of this family cover a broad spectrum of natural bioactivities ranging from antimicrobial and antiviral activities to selective blockage or activation of ion channels, cell surface receptors and extracelluar proteases. In recent years, the spectrum of natural bioactivities of this class of miniproteins was further expanded by application of protein design and directed evolution technologies. Miniproteins have been developed that inhibit platelet aggregation, block asthma-related proteases, act as growth factor mimics or address human tumor targets. Recent reports on miniproteins binding to cancer specific targets indicate that these biomolecules due to their particularly high in vivo stability, high target affinity, good tissue distribution, and fast body clearance are very promising agents that can be endowed with important beneficial features for imaging and therapeutic applications. With the first cystine-knot miniprotein already marketed as an analgesic, more candidates can be expected to find their way into the clinic for diagnostic and therapeutic applications over next years
Export Options
About this article
Cite this article as:
Kolmar Harald, Natural and Engineered Cystine Knot Miniproteins for Diagnostic and Therapeutic Applications, Current Pharmaceutical Design 2011; 17 (38) . https://dx.doi.org/10.2174/138161211798999465
DOI https://dx.doi.org/10.2174/138161211798999465 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma
Combinatorial Chemistry & High Throughput Screening Therapeutic Antibodies and Other Proteins Obtained by Molecular Display Technologies
Recent Patents on Biotechnology Evaluation of HIV-1 Regulatory and Structural Proteins as Antigen Candidate in Mice and Humans
Current HIV Research Subject Index To Volume-3
Letters in Drug Design & Discovery Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Patent Review
Combinatorial Chemistry & High Throughput Screening The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Structural Organization of the Regulatory Domain of Human 5- Lipoxygenase
Current Protein & Peptide Science Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry Biological Activities and Corresponding SARs of Andrographolide and Its Derivatives
Mini-Reviews in Medicinal Chemistry The Inhibitory Co-Receptors: A Way to Save from Anergy the HIVSpecific T Cells
Current HIV Research Neutrophil to Lymphocyte (N/L) and Platelet to Lymphocyte (P/L) Ratios in Differentiating Acute Heart Failure from Respiratory Infection
Current Vascular Pharmacology The Role of Sialylation in Respiratory Viral Infection and Treatment
Current Medicinal Chemistry The Cellular Effects of Carbon Monoxide in the Airway
Current Molecular Medicine Formaldehyde Levels in Fabrics on the Ghanaian Market
Current Materials Science A Novel Antidiabetic Therapy: Free Fatty Acid Receptors as Potential Drug Target
Current Diabetes Reviews Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Trick-or-Treat: Dietary Lipids and Host Resistance to Infectious Disease
Mini-Reviews in Medicinal Chemistry The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued)